Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLOGet Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 1,885 put options on the company. This is an increase of 1,101% compared to the typical volume of 157 put options.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EVLO. Shay Capital LLC bought a new stake in Evelo Biosciences during the 4th quarter worth about $30,000. Barclays PLC grew its position in shares of Evelo Biosciences by 654.2% during the 4th quarter. Barclays PLC now owns 22,641 shares of the company’s stock worth $36,000 after buying an additional 19,639 shares during the period. Walleye Capital LLC acquired a new position in shares of Evelo Biosciences during the 1st quarter worth about $38,000. Boothbay Fund Management LLC acquired a new position in shares of Evelo Biosciences during the 4th quarter worth about $85,000. Finally, Man Group plc acquired a new position in shares of Evelo Biosciences during the 4th quarter worth about $85,000. 0.31% of the stock is owned by institutional investors.

Evelo Biosciences Price Performance

Evelo Biosciences stock opened at $0.05 on Thursday. The stock has a 50-day simple moving average of $0.05 and a 200 day simple moving average of $0.72. Evelo Biosciences has a 12-month low of $0.03 and a 12-month high of $13.93. The stock has a market capitalization of $949,000.00, a price-to-earnings ratio of 0.00 and a beta of 2.03.

About Evelo Biosciences

(Get Free Report)

Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.

Read More

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.